Compare Moderna, Inc. (MRNA) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Xpeng Inc - ADR — how do they compare? Moderna, Inc. trades at $63.69 (market cap $24.18B), while Xpeng Inc - ADR trades at $11.76 (market cap $11.15B). The key difference: Moderna, Inc. is far larger — about 2.2× Xpeng Inc - ADR's market cap, and Moderna, Inc. is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| MRNA | XPEV | |
|---|---|---|
Market Cap | $24.18B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $28.07 |
52-Week Low | $22.36 | $11.68 |
Enterprise Value | $20.33B | $13.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
XPeng (XPEV) trades at $11.74, down 2.17% today, with a bearish technical signal but oversold RSI. Revenue surged to $76.72B in 2025, yet net losses persist at -$1.14B. Recent news highlights July 2026 deliveries of 38,027 vehicles, up 4% YoY, and expansion into robotics and autonomous driving.
Outlook: Analyst consensus is bullish with a $17.00 price target, but risks include intense EV competition and ongoing profitability challenges. Upside hinges on new model success and global expansion, while cash flow volatility and high debt remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
